$3.41
2.16% today
Nasdaq, Apr 03, 06:17 pm CET
ISIN
US49720K1016
Symbol
HURA
Sector
Industry

Kintara Therapeutics Inc Stock price

$3.48
+1.32 61.11% 1M
+0.13 4.00% 6M
-0.61 14.91% YTD
+1.72 98.06% 1Y
-350.90 99.02% 3Y
-342.41 98.99% 5Y
-28,301.02 99.99% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.57 19.59%
ISIN
US49720K1016
Symbol
HURA
Sector
Industry

Key metrics

Market capitalization $152.01m
Enterprise Value $157.35m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-8.45m
Free Cash Flow (TTM) Free Cash Flow $-7.20m
Cash position $4.91m
EPS (TTM) EPS $-75.23
P/E forward negative
Short interest 9.81%
Show more

Is Kintara Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Kintara Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Kintara Therapeutics Inc forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Kintara Therapeutics Inc forecast:

Buy
100%

Financial data from Kintara Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs 0.06 0.06
0% 0%
-
-0.06 -0.06
0% 0%
-
- Selling and Administrative Expenses 5.68 5.68
6% 6%
-
- Research and Development Expense 2.66 2.66
71% 71%
-
-8.40 -8.40
43% 43%
-
- Depreciation and Amortization 0.06 0.06
0% 0%
-
EBIT (Operating Income) EBIT -8.45 -8.45
43% 43%
-
Net Profit -8.32 -8.32
43% 43%
-

In millions USD.

Don't miss a Thing! We will send you all news about Kintara Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Kintara Therapeutics Inc Stock News

Neutral
PRNewsWire
2 days ago
Phase 3 IFx-2.0 accelerated approval trial as adjunctive therapy with Keytruda® (pembrolizumab) in 1st line therapy for advanced Merkel cell carcinoma (MCC) planning to initiate enrollment in Q2 2025 MCC Phase 3 trial to be conducted under Special Protocol Assessment (SPA) Agreement with FDA Acquisition of Kineta's Phase 2 ready, VISTA inhibiting antibody targeted for completion in Q2 2025 Expa...
Neutral
Accesswire
23 days ago
Dr. Tendler oversaw 30 Major Drug Approvals, including worldwide approvals for J&J's transformational treatments in hematologic malignancies, prostate, lung and bladder cancers Dr. Tendler also oversaw 13 FDA Breakthrough Designations accelerating the early development of promising investigational medicines intended for treatment of serious oncology indications TAMPA, FL / ACCESS Newswire / Mar...
Neutral
Accesswire
24 days ago
Live webcast fireside chat on Tuesday, March 18th at 8:30 AM PT TAMPA, FL / ACCESS Newswire / March 10, 2025 / TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that James A. Bianco, M.D.
More Kintara Therapeutics Inc News

Company Profile

Kintara Therapeutics, Inc. is a clinical and biopharmaceutical company, which focuses on the development and commercialization of new cancer therapies. Its pipeline includes the VAL-083 and REM-001. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.

Head office United States
CEO James Bianco
Employees 11
Founded 2009
Website www.tuhurabio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today